Pacira BioSciences (PCRX) said Monday that two-year results from a Phase 1 study showed its gene therapy candidate PCRX-201 provided sustained improvements in pain, stiffness, and function in patients with knee osteoarthritis.
Patients who received corticosteroid pretreatment experienced greater reductions in pain and stiffness, the company said.
PCRX-201, which boosts production of an anti-inflammatory protein, was generally well tolerated, with mild to moderate joint swelling as the most common side effect.
Pacira is currently enrolling patients in a phase 2 study of PCRX-201 for knee osteoarthritis.
Shares of Pacira were up 2.7% in recent trading.
Price: 26.41, Change: +0.69, Percent Change: +2.68
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。